PROFProfound Medical Corp.Healthcare · Medical - Devicesas of 2026-09-16
Horizon

Issued 2026-09-16 at $5.83 · now $5.83 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, PROF has typically landed between $4.35 and $7.54 — a range of −25.3% to +29.3% from the issuance price $5.83.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,708 overlapping 1 month windows · 2019-10-292026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($5.83) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where PROF has typically landed a month from the 2026-09-16 close of $5.83 — the range is history, not a prediction.

$4.35worst · -25.3%$7.54best · +29.3%
  • now $5.83 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $5.74 (-1.5%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $5.09$6.39
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.35$7.54
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,708 windows spanning 2019-10-29 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2020-02-21−59.0%−59.0%+0.0%
2020-02-18−55.7%−55.7%+0.0%
2020-02-19−53.7%−54.3%+1.6%
3 best
2022-11-29+138.2%+0.0%+138.2%
2022-11-30+128.8%+0.0%+129.2%
2022-12-01+123.2%+0.0%+123.2%

1,708 overlapping windows · 2019-10-292026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~7 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
57%
+9.6%
n=7
Feb
71%
−1.5%
n=7
Mar
0%
−16.8%
n=7
Apr
43%
+1.5%
n=7
May
57%
+3.7%
n=7
Jun
57%
+5.7%
n=7
Jul
43%
+2.8%
n=7
Aug
14%
−12.5%
n=7
Sep
43%
−3.8%
n=7
Oct
33%
−2.1%
n=6
Nov
71%
+6.7%
n=7
Dec
71%
+23.4%
n=7

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$9$4↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-05-16Menawat Arun SwarupdirectorPurchase12,027 @ $4.73$57K+2.1% of holding+43.6%+31.7%587,089Form 4 · filed 4 days after the trade
2025-05-15Menawat Arun SwarupdirectorPurchase10,003 @ $4.33$43K+1.8% of holding+47.6%+25.7%575,062Form 4 · filed 5 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.